These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
70 related articles for article (PubMed ID: 26229753)
1. Comparative evaluation of efficacy and safety of combination of metformin-vidagliptin versus metfromin-glimepiride in most frequently used doses in patients of type 2 diabetes mellitus with inadequately controlled metformin monotherapy-A randomised open label study. Gupta S; Khajuria V; Tandon VR; Mahajan A; Gillani ZH Perspect Clin Res; 2015; 6(3):163-8. PubMed ID: 26229753 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P; Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236 [TBL] [Abstract][Full Text] [Related]
3. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. Plosker GL; Figgitt DP Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124 [TBL] [Abstract][Full Text] [Related]
4. Comparative Evaluation of Safety and Efficacy of Glimepiride and Sitagliptin in Combination with Metformin in Patients with Type 2 Diabetes Mellitus: Indian Multicentric Randomized Trial - START Study. Devarajan TV; Venkataraman S; Kandasamy N; Oomman A; Boorugu HK; Karuppiah SKP; Balat D Indian J Endocrinol Metab; 2017; 21(5):745-750. PubMed ID: 28989886 [TBL] [Abstract][Full Text] [Related]
5. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial. Umpierrez G; Issa M; Vlajnic A Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of glimepiride/metformin fixed-dose combination vs metformin uptitration in type 2 diabetic patients inadequately controlled on low-dose metformin monotherapy: A randomized, open label, parallel group, multicenter study in Korea. Kim HS; Kim DM; Cha BS; Park TS; Kim KA; Kim DL; Chung CH; Park JH; Jang HC; Choi DS J Diabetes Investig; 2014 Nov; 5(6):701-8. PubMed ID: 25422771 [TBL] [Abstract][Full Text] [Related]
7. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Ferrannini E; Fonseca V; Zinman B; Matthews D; Ahrén B; Byiers S; Shao Q; Dejager S Diabetes Obes Metab; 2009 Feb; 11(2):157-66. PubMed ID: 19125777 [TBL] [Abstract][Full Text] [Related]
8. Comparison of Safety and Efficacy of Glimepiride-Metformin and Vildagliptin- Metformin Treatment in Newly Diagnosed Type 2 Diabetic Patients. Kumar S Indian J Endocrinol Metab; 2021; 25(4):326-331. PubMed ID: 35136740 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness and Safety of Hydroxychloroquine compared to Teneligliptin in uncontrolled T2DM patients as add-on Therapy. Kumar A; Prakash AS J ASEAN Fed Endocr Soc; 2019; 34(1):87-91. PubMed ID: 33442141 [TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy of glimepiride and metformin in monotherapy of type 2 diabetes mellitus: meta-analysis of randomized controlled trials. Zhu H; Zhu S; Zhang X; Guo Y; Shi Y; Chen Z; Leung SW Diabetol Metab Syndr; 2013 Nov; 5(1):70. PubMed ID: 24228743 [TBL] [Abstract][Full Text] [Related]
11. Diabetes mellitus in the young: Gliptins or sulfonylurea after metformin? Muthukrishnan J; Dawra S; Marwaha V; Bishnoi JS; Narayanan CS Indian J Endocrinol Metab; 2012 Dec; 16(Suppl 2):S474-6. PubMed ID: 23565471 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus. González-Ortiz M; Guerrero-Romero JF; Violante-Ortiz R; Wacher-Rodarte N; Martínez-Abundis E; Aguilar-Salinas C; Islas-Andrade S; Arechavaleta-Granell R; González-Canudas J; Rodríguez-Morán M; Zavala-Suárez E; Ramos-Zavala MG; Metha R; Revilla-Monsalve C; Beltrán-Jaramillo TJ J Diabetes Complications; 2009; 23(6):376-9. PubMed ID: 18849173 [TBL] [Abstract][Full Text] [Related]
13. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Einhorn D; Rendell M; Rosenzweig J; Egan JW; Mathisen AL; Schneider RL Clin Ther; 2000 Dec; 22(12):1395-409. PubMed ID: 11192132 [TBL] [Abstract][Full Text] [Related]
14. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Charpentier G; Fleury F; Kabir M; Vaur L; Halimi S Diabet Med; 2001 Oct; 18(10):828-34. PubMed ID: 11678974 [TBL] [Abstract][Full Text] [Related]
15. Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone. Srivastava S; Saxena GN; Keshwani P; Gupta R J Assoc Physicians India; 2012 Mar; 60():27-30. PubMed ID: 22799111 [TBL] [Abstract][Full Text] [Related]
16. Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin. Hollander P; Hill J; Johnson J; Wei Jiang Z; Golm G; Huyck S; Terra SG; Mancuso JP; Engel SS; Lauring B; Liu J Curr Med Res Opin; 2019 Aug; 35(8):1335-1343. PubMed ID: 30760125 [No Abstract] [Full Text] [Related]
17. Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Luis Bautista J; Bugos C; Dirnberger G; Atherton T Clin Ther; 2003 Jan; 25(1):194-209. PubMed ID: 12637120 [TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Handelsman Y; Lauring B; Gantz I; Iredale C; O'Neill EA; Wei Z; Suryawanshi S; Kaufman KD; Engel SS; Lai E Curr Med Res Opin; 2017 Oct; 33(10):1861-1868. PubMed ID: 28548024 [TBL] [Abstract][Full Text] [Related]
19. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension. Barnett AH; Patel S; Harper R; Toorawa R; Thiemann S; von Eynatten M; Woerle HJ Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280 [TBL] [Abstract][Full Text] [Related]
20. Short-term efficacy and safety of repaglinide versus glimepiride as augmentation of metformin in treating patients with type 2 diabetes mellitus. Xie J; Li N; Jiang X; Chai L; Chen JJ; Deng W Diabetes Metab Syndr Obes; 2019; 12():519-526. PubMed ID: 31114280 [No Abstract] [Full Text] [Related] [Next] [New Search]